The evidence provided by this study supports the stance that the lncRNA PAXIP1-AS1/ETS1/KIF14 axis is implicated in the aggression potential of glioma and may be targeted for the development of therapies. This evidence concerns the gene PAXIP1 and central nervous system cancer.